What's the Outlook for BioNTech Stock?

Zhiyuan Sun, The Motley Fool
·5-min read
What's the Outlook for BioNTech Stock?

As of today, 167 COVID-19 vaccine candidates are in development around the world with 28 in clinical human trials. In response, demand for coronavirus vaccine stocks has soared as investors try to pick the most likely winners of the vaccine race. One of the most promising vaccine candidates is being jointly developed by two large-cap biotech companies, BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE).